TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25017924
Drug: Oral low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral low-dose hormone therapy (estradiol 1 mg + drospirenone 2 mg/day) for 3 months
Study: 20642918
Drug: Walking epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking epidural analgesia with 15 ml of 0.1% Bupivacaine + 0.5 mg/ml Tramadol
Study: 29726480
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (200 μg injected into the coronary artery)
Study: 16107035
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication affecting coagulation)
Study: 12130970
Drug: H2-blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2-blockers
Study: 25088963
Drug: Denosumab 60mg
Normalized name: DENOSUMAB 60MG/ML INJ
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 60mg subcutaneous injections twice yearly
Study: 19906002
Drug: estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol valerate 2 mg + placebo (E/P)
Study: 6780998
Drug: 96 mg
Normalized name: camphor 96 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 96 mg of inhaled cocaine
Study: 8284070
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg
Study: 22038349
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide inhalation (18 μg/day)
Study: 18647853
Drug: Tablet PC
Normalized name: PCS-499
DrugBank: PCS-499 (DB15122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet PC self-administered questionnaires
Study: 2677374
Drug: H142 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H142 at 2.5 mg/kg/h
Study: 3899772
Drug: Prenylamine 60
Normalized name: prenylamine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenylamine 60 mg t.i.d.
Study: 20730486
Drug: Post-treatment fracture
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment fracture rates
Study: 6761102
Drug: High calorie
Normalized name: High calorie formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calorie daily supplement (800 kcal and 40 g protein)
Study: 16244028
Drug: Alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine with 8.4% NaHCO3 (group large dose)
Study: 24992294
Drug: Atazanavir/ritonavir 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir 300/100 mg once daily
Study: 14722892
Drug: Lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 400/100 mg twice daily
Study: 28993264
Drug: Muscarinic-antagonist component
Normalized name: 1,3-beta-glucan synthase component FKS1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscarinic-antagonist component (umeclidinium - UME)
Study: 15673389
Drug: Autonomic tone
Normalized name: docusate
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic tone inhibition (ATI) with propranolol (0.15 mg/kg) and atropine (0.02 mg/kg)
Study: 25765835
Drug: Silymarin supplementation
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin supplementation (140 mg, thrice daily for 45 days)
Study: 9273185
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy and radiotherapy (cisplatin 50 mg/m2 on days 1 and 2, fluorouracil 1 gr/m2 continuous infusion on days 1, 2, and 3, external beam irradiation 20 Gy in 2 Gy fractions from days 1 to 12)
Study: 12612294
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily for 16 weeks
Study: 17894651
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (low exposure category)
Study: 9264481
Drug: Low-dose hirudin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hirudin (0.2 mg/kg bolus + 0.10 mg x kg(‐1) x h(‐1) infusion, n=271)
Study: 17905357
Drug: GengNianAn (GNA)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GengNianAn (GNA) formula, taken twice daily for 12 weeks
Study: 2659293
Drug: Gentamicin 80
Normalized name: gentamicin 80 mg/50 mL-0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 80 mg i.m. twice daily
Study: 10971309
Drug: Dofetilide 1500
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dofetilide 1500 microg, twice daily
Study: 10971309
Drug: Dofetilide 1000
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dofetilide 1000 microg, three times daily
Study: 15040643
Drug: Zidovudine 300
Normalized name: zidovudine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 300 mg twice/day
Study: 9729573
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (6 mg/kg)
Study: 19359073
Drug: L-arginine (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (14 g/day)
Study: 7682088
Drug: Late sequelae
Normalized name: Ferro-Sequels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late sequelae of chemotherapy
Study: 7682088
Drug: Exploration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exploration of drug administration methods
Study: 20430947
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amlodipine and valsartan
Study: 26731258
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (to induce low or high postprandial glycemia)
Study: 3542982
Drug: Rapid parenteral
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid parenteral injections of fluphenazine hydrochloride
Study: 29485533
Drug: Intensive interdisciplinary
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive interdisciplinary pain treatment
Study: 20927038
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day
Study: 12098564
Drug: Interferon-beta (IFN)
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta (IFN) 1b therapy
Study: 6338768
Drug: Ocular decongestant
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular decongestant product 3 (naphazoline hydrochloride + antazoline phosphate or pheniramine maleate)
Study: 17080004
Drug: 8 days
Normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 days of antibiotics
Study: 23681143
Drug: Perioperative IV
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative IV lidocaine (2 mg·kg·h)
Study: 29345398
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (self-selected music using ear-bud headphones during the procedure)
Study: 30685834
Drug: Subarachnoid anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid anesthesia with ketamine 0.75 mg/kg (KE0.75)
Study: 22869065
Drug: GHRH (tesamorelin)
Normalized name: GHRH(1-44)
DrugBank: Somatorelin (DB12656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (tesamorelin) 1 mg/d
Study: 343968
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg fendosal
Study: 12099782
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine or physostigmine
Study: 207295
Drug: practolol injection
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: practolol injection (2 mg kg‐1 for 10 min); salbutamol infusion
Study: 30239799
Drug: Anti-TNF-alpha therapy
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-alpha therapy during pregnancy
Study: 16613190
Drug: Thrombus aspiration
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombus aspiration therapy
Study: 2486951
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid 500 mg every 8 hrs for 5 days
Study: 1810523
Drug: Meclofenamic acid
Normalized name: Meclofenamic Acid
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamic acid suppositories (200 mg) every 12 h during the immediate postsurgical period in gynecological patients.
Study: 21110014
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) 40 mg
Study: 31641074
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Cannula (HFNC) therapy
Study: 29390064
Drug: Clopidogrel or
Normalized name: clopidogrel Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel or Ticagrelor (randomized antiplatelet treatment)
Study: 9194107
Drug: Intravenous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceftazidime plus tobramycin (CAZ/TM)
Study: 9249084
Drug: AGL group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGL group (58 g amino acids + 60 g glycerol)
Study: 19815265
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg once daily with breakfast (de novo treatment)
Study: 21166852
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg/day
Study: 28799226
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention consisting of educational outreach visits with feedback on prescribing and the development of a working procedure on medication reviews (MRs). Follow-up duration was 9 months.
Study: 31549770
Drug: Low-dose-rate brachytherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose-rate brachytherapy
Study: 8204943
Drug: Droloxifene 20
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 20 mg/day
Study: 8204943
Drug: Droloxifene 40
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 40 mg/day
Study: 7676701
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C bound to activated carbon particles (MMC-CH) 50 mg dispersed throughout the peritoneal cavity before surgical closure
Study: 1361795
Drug: Intraperitoneal netilmicin
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal netilmicin and vancomycin (500 and 60-100 mg daily respectively)
Study: 31781230
Drug: Succinate-based dietary
Normalized name: succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinate-based dietary supplement (SBDS; Amberen)
Study: 7962781
Drug: Dodecyl trimethyl
Normalized name: dodecyl benzoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dodecyl trimethyl ammonium bromide (DTAB) 7.5% for 20 minutes daily for 8 days
Study: 2137666
Drug: Sustained-release isradipine
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release isradipine administered once daily
Study: 2137666
Drug: Immediate-release isradipine
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release isradipine administered twice daily
Study: 7946177
Drug: Sustained-release isradipine
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release isradipine
Study: 16267767
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (n=105)
Study: 16267767
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (n=122)
Study: 6577782
Drug: Gemfibrozil therapy
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil therapy
Study: 26813298
Drug: Placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (150 mL 0.9% NaCl)
Study: 9632030
Drug: Fluoxetine 20-60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20-60 mg plus group psychotherapy
Study: 16109116
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 100 mg/d
Study: 21842274
Drug: rizatriptan 10
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rizatriptan 10 mg
Study: 16100154
Drug: Silver Nitrate
Normalized name: Silver Nitrate
DrugBank: Silver (DB12965)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silver Nitrate (20 mL 0.5%)
Study: 16100154
Drug: Talc Slurry
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talc Slurry (5 g diluted to 50 mL with saline)
Study: 24385407
Drug: Other antiplatelet
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiplatelet drugs
Study: 26836244
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone therapy (17β-estradiol combined with norethisterone acetate 0.05 mg + 5 mg/d) for 24 weeks
Study: 3904805
Drug: Tigason at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigason at half of the maximal dose tolerated during the clearing phase of the treatment
Study: 10393137
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium diet (1180 +/‐ 117 mg)
Study: 2082308
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 90 mg
Study: 24500725
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection
Study: 18027674
Drug: Classic method
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic method combined with prunrllae oral solution (group B1)
Study: 11329107
Drug: ACE therapy
Normalized name: Salicylic Acid 0.5 g in 100 mL TOPICAL LIQUID [KOCOSTAR FACE THERAPY ACNE TREATMENT CREAM TO PATCH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE therapy
Study: 28749175
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia to deltoid muscle level; 3‐5 ml
Study: 8203857
Drug: Gram-positive prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gram-positive prophylaxis with 10(6) U of penicillin i.v. every 6 hours (or 750 mg of vancomycin i.v. q12h if penicillin allergic) in addition to standard antimicrobial prophylaxis.
Study: 8559485
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (500 micrograms thrice weekly for 3 months, then 200 micrograms thrice weekly for the next 3 months)
Study: 9666011
Drug: Fluconazole weekly
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole weekly (400 mg)
Study: 19694342
Drug: Enteral diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral diet supplements with arginine and fiber (group I)
Study: 12442604
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution (25 grams carbohydrates)
Study: 25146061
Drug: Royal Jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal Jelly (1000 mg capsule taken orally once daily for two consecutive menstrual cycles)
Study: 30348101
Drug: Tirofiban treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban treatment
Study: 15329426
Drug: Recombinant surfactant
Normalized name: Recombinant surfactant SP-D
DrugBank: Recombinant surfactant protein D (DB18438)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant surfactant protein C-based surfactant (up to four intratracheal doses within 24 hours)
Study: 2611359
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cyclosporine
Study: 8727431
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume (VT) increased to 12-14 ml/kg for 30 min
Study: 8727431
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume (VT) decreased to 6-8 ml/kg for 30 min
Study: 7803885
Drug: Histamine2-receptor antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Histamine2-receptor antagonists
Study: 26627641
Drug: gp100 peptide
Normalized name: Gp100:280-288(288V) peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp100 peptide vaccine
Study: 12743562
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with a standardized latex extract
Study: 17319251
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% plus tramadol 100 mg (Group 2)
Study: 2076398
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg slow-release nifedipine
Study: 26225993
Drug: MVM +
Normalized name: Multivitamin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVM + G
Study: 10701032
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron 100 micrograms/kg at induction (Group 1)
Study: 1589702
Drug: Antacid or
Normalized name: Uni-Antacid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid or placebo medication
Study: 17947301
Drug: Any treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment strategy (without treatment adjustments)
Study: 16456211
Drug: Educational interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational interventions promoting evidence-based supply of non-prescription medicines
Study: 28808847
Drug: Hyoscine N-butyl
Normalized name: n-butyl acrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N-butyl bromide (20 mg, slow intravenous injection)
Study: 12947054
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 day 1 plus gemcitabine 1,250 mg/m2 days 1 and 8, every 3 weeks for six cycles (CG)
Study: 20372991
Drug: Azithromycin tablets
Normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin tablets (fasted state)
Study: 26932797
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication regimen (pantoprazole 40 mg b.i.d., bismuth subcitrate 120 mg q.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d. for 14 days)
Study: 19581281
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment strategy with methotrexate (MTX)
Study: 8942454
Drug: Clozapine at
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine at medium serum level range (200-300 ng/ml)
Study: 9059063
Drug: Treatment period
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period of 32 weeks vs 48 weeks.
Study: 8458096
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose GH treatment (40 units/m2/week)
Study: 9440907
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GH treatment)
Study: 6113352
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir
Study: 11966623
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose (27 mg) of intravesical bacille Calmette-Guérin (BCG)
Study: 7032642
Drug: Sperm-agglutinating antibodies
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sperm-agglutinating antibodies in serum
Study: 15224162
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1000 mg administered intravenously 5 min before surgery)
Study: 3886209
Drug: AVP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AVP infusion